E-cigarette Industry in Malaysia Urges Enforcement of Public Health Law

Feb.08.2025
E-cigarette Industry in Malaysia Urges Enforcement of Public Health Law
Malaysia urged to strengthen enforcement of Public Health Act 2024 for e-cigarettes instead of considering a total ban.

According to a recent report by The Sun, industry insiders in the e-cigarette sector have pointed out that the Malaysian Ministry of Health should focus on strengthening enforcement of the 2024 Public Health Smoking Act (Bill 852) rather than reconsidering the possibility of a complete ban.


Bill 852 regulates the sale, packaging, and use of tobacco products (including e-cigarettes). Ridhwan Rosli, Secretary General of the Malaysian Vape Chamber of Commerce (MVCC), stated that any sudden policy reversal would only exacerbate uncertainty. The e-cigarette industry has always supported responsible regulation and a comprehensive ban has been proven ineffective. Bans cannot eliminate demand, but only push products towards a harder-to-control black market.


Previously, reports indicated that the Ministry of Health is prepared to reconsider a complete ban on e-cigarettes if necessary. Health Minister Dzulkefly Ahmad stated that the priority is to regulate and control the use of e-cigarettes, including through mandatory product registration.


Ross highlighted that the Bill 852 is being implemented in phases, stressing that all stakeholders, including industry participants, should be given enough time to fully adapt to these regulations. Ross explicitly stated that e-cigarette products are intended only for adult smokers who wish to quit. Instead of ineffective bans, it is more important to ensure through education that e-cigarettes are seen as a harm reduction tool rather than a gateway for non-smokers.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Fourth Circuit weighs federal preemption challenge to North Carolina’s vape sales restrictions
Fourth Circuit weighs federal preemption challenge to North Carolina’s vape sales restrictions
Vape manufacturers and sellers urged the U.S. Court of Appeals for the Fourth Circuit to find that the federal Food, Drug, and Cosmetic Act (FDCA) preempts North Carolina’s new law restricting the sale of certain e-cigarette/ENDS products.
Feb.03 by 2FIRSTS.ai
PMI Launches Mass Production of ZYN at $600M Aurora Manufacturing Hub
PMI Launches Mass Production of ZYN at $600M Aurora Manufacturing Hub
Philip Morris International (PMI), through its subsidiary Swedish Match, has started large-scale production at a 600,000-square-foot ZYN nicotine pouch facility in Aurora, Colorado. The $600 million investment makes the site one of three ZYN manufacturing plants in the United States and the company’s second U.S. facility after Owensboro, Kentucky.
PMI
Feb.21
UK South East Seized 3.1M Illegal Vapes Since 2021 as Crackdown Intensifies
UK South East Seized 3.1M Illegal Vapes Since 2021 as Crackdown Intensifies
Illegal vape seizures in the UK South East have risen sharply over the past five years, with 2023 marking the high point. While single-use vapes were banned from sale in June 2025, enforcement teams say disposable products remain in circulation, fueling renewed calls for licensing and stronger enforcement funding.
Jan.23 by 2FIRSTS.ai
France’s ANSES Report Reframes the Vape Debate: Harm Reduction Confirmed, Regulatory Barriers Rising
France’s ANSES Report Reframes the Vape Debate: Harm Reduction Confirmed, Regulatory Barriers Rising
France’s top health agency has confirmed that vaping is less harmful than smoking — but not risk-free — reshaping the country’s regulatory trajectory. As Paris withdraws a proposed vape tax and debates stricter ingredient, emissions and youth-protection rules, the ANSES report signals not prohibition, but tighter technical oversight. For manufacturers, retailers and EU policymakers, France may be previewing Europe’s next phase of nicotine governance.
Special Report
Feb.23
Rethinking Nicotine Harm Reduction: A Neuroscientist’s Perspective on Scientific Gaps and Future Directions — By Dr. Xin-an Liu
Rethinking Nicotine Harm Reduction: A Neuroscientist’s Perspective on Scientific Gaps and Future Directions — By Dr. Xin-an Liu
After France’s ANSES report on nicotine products and harm reduction, Dr. Xin-an Liu wrote to 2Firsts reassessing the field’s foundations. She argues the debate reveals gaps in evidence on long-term behavioral substitution, addiction pathways and neurobiological impacts, and calls for longitudinal research, integrated behavioral science and neuroimaging, clearer risk assessment and stronger transparency to ensure policy and next-generation product development rest on solid evidence.
Industry Insight
Feb.24
Russian consumer group urges Kremlin administration to reject regional vape sales bans
Russian consumer group urges Kremlin administration to reject regional vape sales bans
A Russian consumer organization has urged the Presidential Administration to block proposals that would let regions ban ENDS and e-liquid sales, warning it would create fragmented regulation and turbocharge the illicit market. The group cites WHO statistics and overseas experiences to argue for a more targeted regulatory model.
Feb.06 by 2FIRSTS.ai